GenFleet Therapeutics (Shanghai) Inc. (HKG:2595)

Revenue by Segment

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2023
Period Ending	Dec 31, 2023
Biopharmaceutical Research and Development	73.73M
Total	73.73M

Revenue by Geography

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2023
Period Ending	Dec 31, 2023
Chinese Mainland	71.78M
Overseas	1.96M
Total	73.73M

Source: S&P Global Market Intelligence.